Pharma & Healthcare
Global Andrographolide Drug Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 609297
- Pages: 140
- Figures: 131
- Views: 27
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Andrographolide Drug market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Tasly Group
Furen Pharmaceutical
Jiuhui Pharmaceutical
Sunflower Pharmaceutical
Nanjing Zhengke Pharmaceutical
Livzon Pharm
HORMOSAN Pharma
Segment by Type
Capsule
Pill
Tablet
Segment by Application
Hospital Clinic
Pharmacy
Online Pharmacy
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Andrographolide Drug study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Andrographolide Drug market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Tasly Group
Furen Pharmaceutical
Jiuhui Pharmaceutical
Sunflower Pharmaceutical
Nanjing Zhengke Pharmaceutical
Livzon Pharm
HORMOSAN Pharma
Segment by Type
Capsule
Pill
Tablet
Segment by Application
Hospital Clinic
Pharmacy
Online Pharmacy
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Andrographolide Drug study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Andrographolide Drug: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Andrographolide Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Capsule
1.2.3 Pill
1.2.4 Tablet
1.3 Market Segmentation by Application
1.3.1 Global Andrographolide Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Clinic
1.3.3 Pharmacy
1.3.4 Online Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Andrographolide Drug Revenue Estimates and Forecasts 2020-2031
2.2 Global Andrographolide Drug Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Andrographolide Drug Sales Estimates and Forecasts 2020-2031
2.4 Global Andrographolide Drug Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Andrographolide Drug Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Andrographolide Drug Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Capsule Market Size by Manufacturers
3.5.2 Pill Market Size by Manufacturers
3.5.3 Tablet Market Size by Manufacturers
3.6 Global Andrographolide Drug Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Andrographolide Drug Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Andrographolide Drug Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Andrographolide Drug Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Andrographolide Drug Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Andrographolide Drug Sales and Revenue by Type (2020-2031)
6.4 North America Andrographolide Drug Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Andrographolide Drug Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Andrographolide Drug Sales and Revenue by Type (2020-2031)
7.4 Europe Andrographolide Drug Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Andrographolide Drug Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Andrographolide Drug Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Andrographolide Drug Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Andrographolide Drug Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Andrographolide Drug Sales and Revenue by Type (2020-2031)
9.4 Central and South America Andrographolide Drug Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Andrographolide Drug Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Andrographolide Drug Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Andrographolide Drug Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Andrographolide Drug Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Tasly Group
11.1.1 Tasly Group Corporation Information
11.1.2 Tasly Group Business Overview
11.1.3 Tasly Group Andrographolide Drug Product Models, Descriptions and Specifications
11.1.4 Tasly Group Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Tasly Group Andrographolide Drug Sales by Product in 2024
11.1.6 Tasly Group Andrographolide Drug Sales by Application in 2024
11.1.7 Tasly Group Andrographolide Drug Sales by Geographic Area in 2024
11.1.8 Tasly Group Andrographolide Drug SWOT Analysis
11.1.9 Tasly Group Recent Developments
11.2 Furen Pharmaceutical
11.2.1 Furen Pharmaceutical Corporation Information
11.2.2 Furen Pharmaceutical Business Overview
11.2.3 Furen Pharmaceutical Andrographolide Drug Product Models, Descriptions and Specifications
11.2.4 Furen Pharmaceutical Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Furen Pharmaceutical Andrographolide Drug Sales by Product in 2024
11.2.6 Furen Pharmaceutical Andrographolide Drug Sales by Application in 2024
11.2.7 Furen Pharmaceutical Andrographolide Drug Sales by Geographic Area in 2024
11.2.8 Furen Pharmaceutical Andrographolide Drug SWOT Analysis
11.2.9 Furen Pharmaceutical Recent Developments
11.3 Jiuhui Pharmaceutical
11.3.1 Jiuhui Pharmaceutical Corporation Information
11.3.2 Jiuhui Pharmaceutical Business Overview
11.3.3 Jiuhui Pharmaceutical Andrographolide Drug Product Models, Descriptions and Specifications
11.3.4 Jiuhui Pharmaceutical Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Jiuhui Pharmaceutical Andrographolide Drug Sales by Product in 2024
11.3.6 Jiuhui Pharmaceutical Andrographolide Drug Sales by Application in 2024
11.3.7 Jiuhui Pharmaceutical Andrographolide Drug Sales by Geographic Area in 2024
11.3.8 Jiuhui Pharmaceutical Andrographolide Drug SWOT Analysis
11.3.9 Jiuhui Pharmaceutical Recent Developments
11.4 Sunflower Pharmaceutical
11.4.1 Sunflower Pharmaceutical Corporation Information
11.4.2 Sunflower Pharmaceutical Business Overview
11.4.3 Sunflower Pharmaceutical Andrographolide Drug Product Models, Descriptions and Specifications
11.4.4 Sunflower Pharmaceutical Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Sunflower Pharmaceutical Andrographolide Drug Sales by Product in 2024
11.4.6 Sunflower Pharmaceutical Andrographolide Drug Sales by Application in 2024
11.4.7 Sunflower Pharmaceutical Andrographolide Drug Sales by Geographic Area in 2024
11.4.8 Sunflower Pharmaceutical Andrographolide Drug SWOT Analysis
11.4.9 Sunflower Pharmaceutical Recent Developments
11.5 Nanjing Zhengke Pharmaceutical
11.5.1 Nanjing Zhengke Pharmaceutical Corporation Information
11.5.2 Nanjing Zhengke Pharmaceutical Business Overview
11.5.3 Nanjing Zhengke Pharmaceutical Andrographolide Drug Product Models, Descriptions and Specifications
11.5.4 Nanjing Zhengke Pharmaceutical Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Nanjing Zhengke Pharmaceutical Andrographolide Drug Sales by Product in 2024
11.5.6 Nanjing Zhengke Pharmaceutical Andrographolide Drug Sales by Application in 2024
11.5.7 Nanjing Zhengke Pharmaceutical Andrographolide Drug Sales by Geographic Area in 2024
11.5.8 Nanjing Zhengke Pharmaceutical Andrographolide Drug SWOT Analysis
11.5.9 Nanjing Zhengke Pharmaceutical Recent Developments
11.6 Livzon Pharm
11.6.1 Livzon Pharm Corporation Information
11.6.2 Livzon Pharm Business Overview
11.6.3 Livzon Pharm Andrographolide Drug Product Models, Descriptions and Specifications
11.6.4 Livzon Pharm Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Livzon Pharm Recent Developments
11.7 HORMOSAN Pharma
11.7.1 HORMOSAN Pharma Corporation Information
11.7.2 HORMOSAN Pharma Business Overview
11.7.3 HORMOSAN Pharma Andrographolide Drug Product Models, Descriptions and Specifications
11.7.4 HORMOSAN Pharma Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 HORMOSAN Pharma Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Andrographolide Drug Industry Chain
12.2 Andrographolide Drug Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Andrographolide Drug Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Andrographolide Drug Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Andrographolide Drug Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Andrographolide Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Andrographolide Drug: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Andrographolide Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Capsule
1.2.3 Pill
1.2.4 Tablet
1.3 Market Segmentation by Application
1.3.1 Global Andrographolide Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Clinic
1.3.3 Pharmacy
1.3.4 Online Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Andrographolide Drug Revenue Estimates and Forecasts 2020-2031
2.2 Global Andrographolide Drug Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Andrographolide Drug Sales Estimates and Forecasts 2020-2031
2.4 Global Andrographolide Drug Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Andrographolide Drug Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Andrographolide Drug Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Capsule Market Size by Manufacturers
3.5.2 Pill Market Size by Manufacturers
3.5.3 Tablet Market Size by Manufacturers
3.6 Global Andrographolide Drug Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Andrographolide Drug Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Andrographolide Drug Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Andrographolide Drug Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Andrographolide Drug Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Andrographolide Drug Sales and Revenue by Type (2020-2031)
6.4 North America Andrographolide Drug Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Andrographolide Drug Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Andrographolide Drug Sales and Revenue by Type (2020-2031)
7.4 Europe Andrographolide Drug Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Andrographolide Drug Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Andrographolide Drug Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Andrographolide Drug Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Andrographolide Drug Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Andrographolide Drug Sales and Revenue by Type (2020-2031)
9.4 Central and South America Andrographolide Drug Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Andrographolide Drug Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Andrographolide Drug Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Andrographolide Drug Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Andrographolide Drug Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Tasly Group
11.1.1 Tasly Group Corporation Information
11.1.2 Tasly Group Business Overview
11.1.3 Tasly Group Andrographolide Drug Product Models, Descriptions and Specifications
11.1.4 Tasly Group Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Tasly Group Andrographolide Drug Sales by Product in 2024
11.1.6 Tasly Group Andrographolide Drug Sales by Application in 2024
11.1.7 Tasly Group Andrographolide Drug Sales by Geographic Area in 2024
11.1.8 Tasly Group Andrographolide Drug SWOT Analysis
11.1.9 Tasly Group Recent Developments
11.2 Furen Pharmaceutical
11.2.1 Furen Pharmaceutical Corporation Information
11.2.2 Furen Pharmaceutical Business Overview
11.2.3 Furen Pharmaceutical Andrographolide Drug Product Models, Descriptions and Specifications
11.2.4 Furen Pharmaceutical Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Furen Pharmaceutical Andrographolide Drug Sales by Product in 2024
11.2.6 Furen Pharmaceutical Andrographolide Drug Sales by Application in 2024
11.2.7 Furen Pharmaceutical Andrographolide Drug Sales by Geographic Area in 2024
11.2.8 Furen Pharmaceutical Andrographolide Drug SWOT Analysis
11.2.9 Furen Pharmaceutical Recent Developments
11.3 Jiuhui Pharmaceutical
11.3.1 Jiuhui Pharmaceutical Corporation Information
11.3.2 Jiuhui Pharmaceutical Business Overview
11.3.3 Jiuhui Pharmaceutical Andrographolide Drug Product Models, Descriptions and Specifications
11.3.4 Jiuhui Pharmaceutical Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Jiuhui Pharmaceutical Andrographolide Drug Sales by Product in 2024
11.3.6 Jiuhui Pharmaceutical Andrographolide Drug Sales by Application in 2024
11.3.7 Jiuhui Pharmaceutical Andrographolide Drug Sales by Geographic Area in 2024
11.3.8 Jiuhui Pharmaceutical Andrographolide Drug SWOT Analysis
11.3.9 Jiuhui Pharmaceutical Recent Developments
11.4 Sunflower Pharmaceutical
11.4.1 Sunflower Pharmaceutical Corporation Information
11.4.2 Sunflower Pharmaceutical Business Overview
11.4.3 Sunflower Pharmaceutical Andrographolide Drug Product Models, Descriptions and Specifications
11.4.4 Sunflower Pharmaceutical Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Sunflower Pharmaceutical Andrographolide Drug Sales by Product in 2024
11.4.6 Sunflower Pharmaceutical Andrographolide Drug Sales by Application in 2024
11.4.7 Sunflower Pharmaceutical Andrographolide Drug Sales by Geographic Area in 2024
11.4.8 Sunflower Pharmaceutical Andrographolide Drug SWOT Analysis
11.4.9 Sunflower Pharmaceutical Recent Developments
11.5 Nanjing Zhengke Pharmaceutical
11.5.1 Nanjing Zhengke Pharmaceutical Corporation Information
11.5.2 Nanjing Zhengke Pharmaceutical Business Overview
11.5.3 Nanjing Zhengke Pharmaceutical Andrographolide Drug Product Models, Descriptions and Specifications
11.5.4 Nanjing Zhengke Pharmaceutical Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Nanjing Zhengke Pharmaceutical Andrographolide Drug Sales by Product in 2024
11.5.6 Nanjing Zhengke Pharmaceutical Andrographolide Drug Sales by Application in 2024
11.5.7 Nanjing Zhengke Pharmaceutical Andrographolide Drug Sales by Geographic Area in 2024
11.5.8 Nanjing Zhengke Pharmaceutical Andrographolide Drug SWOT Analysis
11.5.9 Nanjing Zhengke Pharmaceutical Recent Developments
11.6 Livzon Pharm
11.6.1 Livzon Pharm Corporation Information
11.6.2 Livzon Pharm Business Overview
11.6.3 Livzon Pharm Andrographolide Drug Product Models, Descriptions and Specifications
11.6.4 Livzon Pharm Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Livzon Pharm Recent Developments
11.7 HORMOSAN Pharma
11.7.1 HORMOSAN Pharma Corporation Information
11.7.2 HORMOSAN Pharma Business Overview
11.7.3 HORMOSAN Pharma Andrographolide Drug Product Models, Descriptions and Specifications
11.7.4 HORMOSAN Pharma Andrographolide Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 HORMOSAN Pharma Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Andrographolide Drug Industry Chain
12.2 Andrographolide Drug Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Andrographolide Drug Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Andrographolide Drug Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Andrographolide Drug Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Andrographolide Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Andrographolide Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Andrographolide Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Andrographolide Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Andrographolide Drug Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Andrographolide Drug Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Andrographolide Drug Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Andrographolide Drug Sales by Region (2020-2025) & (K Units)
Table 8. Global Andrographolide Drug Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Andrographolide Drug Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Andrographolide Drug Sales Share by Manufacturers (2020-2025)
Table 12. Global Andrographolide Drug Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Andrographolide Drug Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Andrographolide Drug by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Andrographolide Drug as of 2024)
Table 16. Global Andrographolide Drug Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Andrographolide Drug Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Andrographolide Drug Manufacturing Base and Headquarters
Table 19. Global Andrographolide Drug Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Andrographolide Drug Sales by Type (2020-2025) & (K Units)
Table 23. Global Andrographolide Drug Sales by Type (2026-2031) & (K Units)
Table 24. Global Andrographolide Drug Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Andrographolide Drug Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Andrographolide Drug ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Andrographolide Drug Sales by Application (2020-2025) & (K Units)
Table 29. Global Andrographolide Drug Sales by Application (2026-2031) & (K Units)
Table 30. Andrographolide Drug High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Andrographolide Drug Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Andrographolide Drug Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Andrographolide Drug ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Andrographolide Drug Growth Accelerators and Market Barriers
Table 37. North America Andrographolide Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Andrographolide Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Andrographolide Drug Growth Accelerators and Market Barriers
Table 40. Europe Andrographolide Drug Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Andrographolide Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Andrographolide Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Andrographolide Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Andrographolide Drug Growth Accelerators and Market Barriers
Table 45. Southeast Asia Andrographolide Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Andrographolide Drug Investment Opportunities and Key Challenges
Table 47. Central and South America Andrographolide Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Andrographolide Drug Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Andrographolide Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Tasly Group Corporation Information
Table 51. Tasly Group Description and Major Businesses
Table 52. Tasly Group Product Models, Descriptions and Specifications
Table 53. Tasly Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Tasly Group Sales Value Proportion by Product in 2024
Table 55. Tasly Group Sales Value Proportion by Application in 2024
Table 56. Tasly Group Sales Value Proportion by Geographic Area in 2024
Table 57. Tasly Group Andrographolide Drug SWOT Analysis
Table 58. Tasly Group Recent Developments
Table 59. Furen Pharmaceutical Corporation Information
Table 60. Furen Pharmaceutical Description and Major Businesses
Table 61. Furen Pharmaceutical Product Models, Descriptions and Specifications
Table 62. Furen Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Furen Pharmaceutical Sales Value Proportion by Product in 2024
Table 64. Furen Pharmaceutical Sales Value Proportion by Application in 2024
Table 65. Furen Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 66. Furen Pharmaceutical Andrographolide Drug SWOT Analysis
Table 67. Furen Pharmaceutical Recent Developments
Table 68. Jiuhui Pharmaceutical Corporation Information
Table 69. Jiuhui Pharmaceutical Description and Major Businesses
Table 70. Jiuhui Pharmaceutical Product Models, Descriptions and Specifications
Table 71. Jiuhui Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Jiuhui Pharmaceutical Sales Value Proportion by Product in 2024
Table 73. Jiuhui Pharmaceutical Sales Value Proportion by Application in 2024
Table 74. Jiuhui Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 75. Jiuhui Pharmaceutical Andrographolide Drug SWOT Analysis
Table 76. Jiuhui Pharmaceutical Recent Developments
Table 77. Sunflower Pharmaceutical Corporation Information
Table 78. Sunflower Pharmaceutical Description and Major Businesses
Table 79. Sunflower Pharmaceutical Product Models, Descriptions and Specifications
Table 80. Sunflower Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Sunflower Pharmaceutical Sales Value Proportion by Product in 2024
Table 82. Sunflower Pharmaceutical Sales Value Proportion by Application in 2024
Table 83. Sunflower Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 84. Sunflower Pharmaceutical Andrographolide Drug SWOT Analysis
Table 85. Sunflower Pharmaceutical Recent Developments
Table 86. Nanjing Zhengke Pharmaceutical Corporation Information
Table 87. Nanjing Zhengke Pharmaceutical Description and Major Businesses
Table 88. Nanjing Zhengke Pharmaceutical Product Models, Descriptions and Specifications
Table 89. Nanjing Zhengke Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Nanjing Zhengke Pharmaceutical Sales Value Proportion by Product in 2024
Table 91. Nanjing Zhengke Pharmaceutical Sales Value Proportion by Application in 2024
Table 92. Nanjing Zhengke Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 93. Nanjing Zhengke Pharmaceutical Andrographolide Drug SWOT Analysis
Table 94. Nanjing Zhengke Pharmaceutical Recent Developments
Table 95. Livzon Pharm Corporation Information
Table 96. Livzon Pharm Description and Major Businesses
Table 97. Livzon Pharm Product Models, Descriptions and Specifications
Table 98. Livzon Pharm Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Livzon Pharm Recent Developments
Table 100. HORMOSAN Pharma Corporation Information
Table 101. HORMOSAN Pharma Description and Major Businesses
Table 102. HORMOSAN Pharma Product Models, Descriptions and Specifications
Table 103. HORMOSAN Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. HORMOSAN Pharma Recent Developments
Table 105. Key Raw Materials Distribution
Table 106. Raw Materials Key Suppliers
Table 107. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 108. Milestones in Production Technology Evolution
Table 109. Distributors List
Table 110. Market Trends and Market Evolution
Table 111. Market Drivers and Opportunities
Table 112. Market Challenges, Risks, and Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Andrographolide Drug Product Picture
Figure 2. Global Andrographolide Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Capsule Product Picture
Figure 4. Pill Product Picture
Figure 5. Tablet Product Picture
Figure 6. Global Andrographolide Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital Clinic
Figure 8. Pharmacy
Figure 9. Online Pharmacy
Figure 10. Andrographolide Drug Report Years Considered
Figure 11. Global Andrographolide Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 13. Global Andrographolide Drug Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Andrographolide Drug Revenue Market Share by Region (2020-2031)
Figure 15. Global Andrographolide Drug Sales (2020-2031) & (K Units)
Figure 16. Global Andrographolide Drug Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Andrographolide Drug Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Andrographolide Drug Sales Volume Market Share in 2024
Figure 19. Global Andrographolide Drug Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Capsule Revenue Market Share by Manufacturer in 2024
Figure 22. Pill Revenue Market Share by Manufacturer in 2024
Figure 23. Tablet Revenue Market Share by Manufacturer in 2024
Figure 24. Global Andrographolide Drug Sales Market Share by Type (2020-2031)
Figure 25. Global Andrographolide Drug Revenue Market Share by Type (2020-2031)
Figure 26. Global Andrographolide Drug Sales Market Share by Application (2020-2031)
Figure 27. Global Andrographolide Drug Revenue Market Share by Application (2020-2031)
Figure 28. North America Andrographolide Drug Sales YoY (2020-2031) & (K Units)
Figure 29. North America Andrographolide Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Andrographolide Drug Sales Revenue (US$ Million) in 2024
Figure 31. North America Andrographolide Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America Andrographolide Drug Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Andrographolide Drug Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America Andrographolide Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Andrographolide Drug Sales YoY (2020-2031) & (K Units)
Figure 39. Europe Andrographolide Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Andrographolide Drug Sales Revenue (US$ Million) in 2024
Figure 41. Europe Andrographolide Drug Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe Andrographolide Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Andrographolide Drug Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe Andrographolide Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 46. France Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Andrographolide Drug Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific Andrographolide Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Andrographolide Drug Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Andrographolide Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific Andrographolide Drug Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Andrographolide Drug Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific Andrographolide Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 61. India Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Andrographolide Drug Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America Andrographolide Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Andrographolide Drug Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Andrographolide Drug Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America Andrographolide Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Andrographolide Drug Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America Andrographolide Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Andrographolide Drug Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa Andrographolide Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Andrographolide Drug Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Andrographolide Drug Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America Andrographolide Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Andrographolide Drug Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa Andrographolide Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 82. Andrographolide Drug Industry Chain Mapping
Figure 83. Regional Andrographolide Drug Manufacturing Base Distribution (%)
Figure 84. Global Andrographolide Drug Production Market Share by Region (2020-2031)
Figure 85. Andrographolide Drug Production Process
Figure 86. Regional Andrographolide Drug Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Table 1. Global Andrographolide Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Andrographolide Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Andrographolide Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Andrographolide Drug Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Andrographolide Drug Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Andrographolide Drug Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Andrographolide Drug Sales by Region (2020-2025) & (K Units)
Table 8. Global Andrographolide Drug Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Andrographolide Drug Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Andrographolide Drug Sales Share by Manufacturers (2020-2025)
Table 12. Global Andrographolide Drug Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Andrographolide Drug Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Andrographolide Drug by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Andrographolide Drug as of 2024)
Table 16. Global Andrographolide Drug Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Andrographolide Drug Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Andrographolide Drug Manufacturing Base and Headquarters
Table 19. Global Andrographolide Drug Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Andrographolide Drug Sales by Type (2020-2025) & (K Units)
Table 23. Global Andrographolide Drug Sales by Type (2026-2031) & (K Units)
Table 24. Global Andrographolide Drug Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Andrographolide Drug Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Andrographolide Drug ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Andrographolide Drug Sales by Application (2020-2025) & (K Units)
Table 29. Global Andrographolide Drug Sales by Application (2026-2031) & (K Units)
Table 30. Andrographolide Drug High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Andrographolide Drug Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Andrographolide Drug Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Andrographolide Drug ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Andrographolide Drug Growth Accelerators and Market Barriers
Table 37. North America Andrographolide Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Andrographolide Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Andrographolide Drug Growth Accelerators and Market Barriers
Table 40. Europe Andrographolide Drug Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Andrographolide Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Andrographolide Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Andrographolide Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Andrographolide Drug Growth Accelerators and Market Barriers
Table 45. Southeast Asia Andrographolide Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Andrographolide Drug Investment Opportunities and Key Challenges
Table 47. Central and South America Andrographolide Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Andrographolide Drug Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Andrographolide Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Tasly Group Corporation Information
Table 51. Tasly Group Description and Major Businesses
Table 52. Tasly Group Product Models, Descriptions and Specifications
Table 53. Tasly Group Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Tasly Group Sales Value Proportion by Product in 2024
Table 55. Tasly Group Sales Value Proportion by Application in 2024
Table 56. Tasly Group Sales Value Proportion by Geographic Area in 2024
Table 57. Tasly Group Andrographolide Drug SWOT Analysis
Table 58. Tasly Group Recent Developments
Table 59. Furen Pharmaceutical Corporation Information
Table 60. Furen Pharmaceutical Description and Major Businesses
Table 61. Furen Pharmaceutical Product Models, Descriptions and Specifications
Table 62. Furen Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Furen Pharmaceutical Sales Value Proportion by Product in 2024
Table 64. Furen Pharmaceutical Sales Value Proportion by Application in 2024
Table 65. Furen Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 66. Furen Pharmaceutical Andrographolide Drug SWOT Analysis
Table 67. Furen Pharmaceutical Recent Developments
Table 68. Jiuhui Pharmaceutical Corporation Information
Table 69. Jiuhui Pharmaceutical Description and Major Businesses
Table 70. Jiuhui Pharmaceutical Product Models, Descriptions and Specifications
Table 71. Jiuhui Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Jiuhui Pharmaceutical Sales Value Proportion by Product in 2024
Table 73. Jiuhui Pharmaceutical Sales Value Proportion by Application in 2024
Table 74. Jiuhui Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 75. Jiuhui Pharmaceutical Andrographolide Drug SWOT Analysis
Table 76. Jiuhui Pharmaceutical Recent Developments
Table 77. Sunflower Pharmaceutical Corporation Information
Table 78. Sunflower Pharmaceutical Description and Major Businesses
Table 79. Sunflower Pharmaceutical Product Models, Descriptions and Specifications
Table 80. Sunflower Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Sunflower Pharmaceutical Sales Value Proportion by Product in 2024
Table 82. Sunflower Pharmaceutical Sales Value Proportion by Application in 2024
Table 83. Sunflower Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 84. Sunflower Pharmaceutical Andrographolide Drug SWOT Analysis
Table 85. Sunflower Pharmaceutical Recent Developments
Table 86. Nanjing Zhengke Pharmaceutical Corporation Information
Table 87. Nanjing Zhengke Pharmaceutical Description and Major Businesses
Table 88. Nanjing Zhengke Pharmaceutical Product Models, Descriptions and Specifications
Table 89. Nanjing Zhengke Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Nanjing Zhengke Pharmaceutical Sales Value Proportion by Product in 2024
Table 91. Nanjing Zhengke Pharmaceutical Sales Value Proportion by Application in 2024
Table 92. Nanjing Zhengke Pharmaceutical Sales Value Proportion by Geographic Area in 2024
Table 93. Nanjing Zhengke Pharmaceutical Andrographolide Drug SWOT Analysis
Table 94. Nanjing Zhengke Pharmaceutical Recent Developments
Table 95. Livzon Pharm Corporation Information
Table 96. Livzon Pharm Description and Major Businesses
Table 97. Livzon Pharm Product Models, Descriptions and Specifications
Table 98. Livzon Pharm Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Livzon Pharm Recent Developments
Table 100. HORMOSAN Pharma Corporation Information
Table 101. HORMOSAN Pharma Description and Major Businesses
Table 102. HORMOSAN Pharma Product Models, Descriptions and Specifications
Table 103. HORMOSAN Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. HORMOSAN Pharma Recent Developments
Table 105. Key Raw Materials Distribution
Table 106. Raw Materials Key Suppliers
Table 107. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 108. Milestones in Production Technology Evolution
Table 109. Distributors List
Table 110. Market Trends and Market Evolution
Table 111. Market Drivers and Opportunities
Table 112. Market Challenges, Risks, and Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Andrographolide Drug Product Picture
Figure 2. Global Andrographolide Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Capsule Product Picture
Figure 4. Pill Product Picture
Figure 5. Tablet Product Picture
Figure 6. Global Andrographolide Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital Clinic
Figure 8. Pharmacy
Figure 9. Online Pharmacy
Figure 10. Andrographolide Drug Report Years Considered
Figure 11. Global Andrographolide Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 13. Global Andrographolide Drug Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Andrographolide Drug Revenue Market Share by Region (2020-2031)
Figure 15. Global Andrographolide Drug Sales (2020-2031) & (K Units)
Figure 16. Global Andrographolide Drug Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Andrographolide Drug Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Andrographolide Drug Sales Volume Market Share in 2024
Figure 19. Global Andrographolide Drug Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Capsule Revenue Market Share by Manufacturer in 2024
Figure 22. Pill Revenue Market Share by Manufacturer in 2024
Figure 23. Tablet Revenue Market Share by Manufacturer in 2024
Figure 24. Global Andrographolide Drug Sales Market Share by Type (2020-2031)
Figure 25. Global Andrographolide Drug Revenue Market Share by Type (2020-2031)
Figure 26. Global Andrographolide Drug Sales Market Share by Application (2020-2031)
Figure 27. Global Andrographolide Drug Revenue Market Share by Application (2020-2031)
Figure 28. North America Andrographolide Drug Sales YoY (2020-2031) & (K Units)
Figure 29. North America Andrographolide Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Andrographolide Drug Sales Revenue (US$ Million) in 2024
Figure 31. North America Andrographolide Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America Andrographolide Drug Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Andrographolide Drug Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America Andrographolide Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Andrographolide Drug Sales YoY (2020-2031) & (K Units)
Figure 39. Europe Andrographolide Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Andrographolide Drug Sales Revenue (US$ Million) in 2024
Figure 41. Europe Andrographolide Drug Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe Andrographolide Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Andrographolide Drug Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe Andrographolide Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 46. France Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Andrographolide Drug Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific Andrographolide Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Andrographolide Drug Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Andrographolide Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific Andrographolide Drug Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Andrographolide Drug Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific Andrographolide Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 61. India Andrographolide Drug Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Andrographolide Drug Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America Andrographolide Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Andrographolide Drug Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Andrographolide Drug Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America Andrographolide Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Andrographolide Drug Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America Andrographolide Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Andrographolide Drug Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa Andrographolide Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Andrographolide Drug Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Andrographolide Drug Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America Andrographolide Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Andrographolide Drug Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa Andrographolide Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Andrographolide Drug Revenue (2020-2025) & (US$ Million)
Figure 82. Andrographolide Drug Industry Chain Mapping
Figure 83. Regional Andrographolide Drug Manufacturing Base Distribution (%)
Figure 84. Global Andrographolide Drug Production Market Share by Region (2020-2031)
Figure 85. Andrographolide Drug Production Process
Figure 86. Regional Andrographolide Drug Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Potassium Bromide Windows Market Research Report 2025
Dec 14, 25
Global Bio-based 1,10-Decanediol Diacrylate Market Research Report 2025
Dec 14, 25
Global Bio-based 1,5-Pentanediol Diacrylate(PDDA) Market Research Report 2025
Dec 14, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232